In a report released on December 21, Jon Berggren from Kepler Capital maintained a Buy rating on Calliditas Therapeutics (CALT – Research Report), with a price target of SEK150.00. The company’s shares closed yesterday at $27.17.
According to TipRanks, Berggren is an analyst with an average return of -16.3% and a 36.00% success rate.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Calliditas Therapeutics with a $40.94 average price target, implying a 50.68% upside from current levels. In a report released on December 21, Stifel Nicolaus also maintained a Buy rating on the stock with a $55.00 price target.
See the top stocks recommended by analysts >>
CALT market cap is currently $696M and has a P/E ratio of -16.05.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Calliditas Therapeutics (CALT) Company Description:
Calliditas Therapeutics AB operates as a specialty pharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys.
Read More on CALT:
